New discovery of biomarker to improve diagnosis, prognosis and treatment of esophageal squamous cell carcinoma

January 6, 2014, National University of Singapore

Esophageal squamous cell carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.

Led by Dr Polly Chen from the Cancer Science Institute of Singapore (CSI Singapore) at NUS, the team is also the first to demonstrate that the editing of protein-making sequences promotes the development of ESCC. This novel study was first published online in Cancer Research on 4 December 2013.

Currently, there is poor prognosis for ESCC patients and the five-year overall survival rate ranges from 20 to 30 per cent. As such, there is an urgent need for biomarkers which can diagnose this disease as early as possible, estimate reaction to chemotherapy or radiotherapy in patients and predict the overall survival rate of patients undergoing treatment.

In normal human cells, deoxyribonucleic acid (DNA), which comprises the genetic code, serves as a template for the precise production of ribonucleic acid (RNA) such that the DNA code and RNA code are identical. Editing is a process in which RNA is changed after it is made from DNA, resulting in an altered gene product. This RNA editing is likely to play a role in the formation of tumours by either inactivating a tumour suppressor or activating genes that promote tumour progression.

In their study, the NUS researchers discovered that the RNA editing enzyme ADAR1, which catalyses the editing process, is significantly over-expressed in ESCC tumours. They observed that ADAR1 changes the product of the AZIN1 protein to a form which promotes the development of the disease. Clinically, the tumoural over-expression of ADAR1 was correlated with the shorter survival time of ESCC patients.

The findings suggest that ADAR1 can serve as a useful biomarker to detect disorders leading to ESCC and as a potential therapeutic target. The study may also provide the key to a biological process for drug development in the treatment of ESCC

Said Dr Chen, "Investigating the connection between ADAR1-mediated RNA editing and progression is only the initial step in this research. The tumoural over-expression of ADAR1 can be used as an early warning sign of ESCC and halting or reversing the process may block the cells' conversion from normal to malignant.

Moving forward, the researchers will further investigate the key RNA editing events regulated by ADAR1 during ESCC development. They plan to develop a method to correct the RNA editing process through restoring ADAR balance by silencing ADAR1 and reinstating a specific hyper-edited or hypo-edited transcript.

Explore further: Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia

More information: "Adenosine-to-Inosine RNA Editing Mediated by ADARs in Esophageal Squamous Cell Carcinoma." Yan-Ru Qin, Jun-Jing Qiao, Tim Hon Man Chan, Ying-Hui Zhu, Fang-Fang Li, Haibo Liu, Jing Fei, Yan Li, Xin-Yuan Guan, and Leilei Chen. Cancer Research. Published Online First December 3, 2013; DOI: 10.1158/0008-5472.CAN-13-2545

Related Stories

Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia

December 24, 2012
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth ...

New startup looking to cure genetic diseases by editing genes in new way

December 4, 2013
(Medical Xpress)—A new startup company called Editas Medicine (with $43 million in funding) is looking to expand on research that has already led to a system called Clustered Regularly Interspaced Short Palindromic Repeats/Cas ...

Recommended for you

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.